Search

Your search keyword '"Tognon, Cristina E."' showing total 320 results
Start Over Author "Tognon, Cristina E." Publication Year Range Last 10 years
320 results on '"Tognon, Cristina E."'

1. Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium

Author

Pikman, Yana, Tasian, Sarah K, Sulis, Maria Luisa, Stevenson, Kristen, Blonquist, Traci M, Apsel Winger, Beth, Cooper, Todd M, Pauly, Melinda, Maloney, Kelly W, Burke, Michael J, Brown, Patrick A, Gossai, Nathan, McNeer, Jennifer L, Shukla, Neerav N, Cole, Peter D, Kahn, Justine M, Chen, Jing, Barth, Matthew J, Magee, Jeffrey A, Gennarini, Lisa, Adhav, Asmani A, Clinton, Catherine M, Ocasio-Martinez, Nicole, Gotti, Giacomo, Li, Yuting, Lin, Shan, Imamovic, Alma, Tognon, Cristina E, Patel, Tasleema, Faust, Haley L, Contreras, Cristina F, Cremer, Anjali, Cortopassi, Wilian A, Garrido Ruiz, Diego, Jacobson, Matthew P, Dharia, Neekesh V, Su, Angela, Robichaud, Amanda L, Saur Conway, Amy, Tarlock, Katherine, Stieglitz, Elliot, Place, Andrew E, Puissant, Alexandre, Hunger, Stephen P, Kim, Annette S, Lindeman, Neal I, Gore, Lia, Janeway, Katherine A, Silverman, Lewis B, Tyner, Jeffrey W, Harris, Marian H, Loh, Mignon L, and Stegmaier, Kimberly

Subjects
Cancer, Rare Diseases, Human Genome, Genetics, Clinical Trials and Supportive Activities, Orphan Drug, Biotechnology, Hematology, Clinical Research, Pediatric Cancer, Childhood Leukemia, Pediatric, Development of treatments and therapeutic interventions, Aetiology, 5.1 Pharmaceuticals, 2.1 Biological and endogenous factors, Good Health and Well Being, Biomarkers, Tumor, Child, Cohort Studies, Disease Progression, Feasibility Studies, Female, Humans, Leukemia, Male, Molecular Targeted Therapy, Neoplasm Recurrence, Local, Prospective Studies, United States, Oncology and Carcinogenesis
Abstract

Despite a remarkable increase in the genomic profiling of cancer, integration of genomic discoveries into clinical care has lagged behind. We report the feasibility of rapid identification of targetable mutations in 153 pediatric patients with relapsed/refractory or high-risk leukemias enrolled on a prospective clinical trial conducted by the LEAP Consortium. Eighteen percent of patients had a high confidence Tier 1 or 2 recommendation. We describe clinical responses in the 14% of patients with relapsed/refractory leukemia who received the matched targeted therapy. Further, in order to inform future targeted therapy for patients, we validated variants of uncertain significance, performed ex vivo drug-sensitivity testing in patient leukemia samples, and identified new combinations of targeted therapies in cell lines and patient-derived xenograft models. These data and our collaborative approach should inform the design of future precision medicine trials. SIGNIFICANCE: Patients with relapsed/refractory leukemias face limited treatment options. Systematic integration of precision medicine efforts can inform therapy. We report the feasibility of identifying targetable mutations in children with leukemia and describe correlative biology studies validating therapeutic hypotheses and novel mutations.See related commentary by Bornhauser and Bourquin, p. 1322.This article is highlighted in the In This Issue feature, p. 1307.

Published
2021

2. An expanded universe of cancer targets

Author

Hahn, William C, Bader, Joel S, Braun, Theodore P, Califano, Andrea, Clemons, Paul A, Druker, Brian J, Ewald, Andrew J, Fu, Haian, Jagu, Subhashini, Kemp, Christopher J, Kim, William, Kuo, Calvin J, McManus, Michael T, B. Mills, Gordon, Mo, Xiulei, Sahni, Nidhi, Schreiber, Stuart L, Talamas, Jessica A, Tamayo, Pablo, Tyner, Jeffrey W, Wagner, Bridget K, Weiss, William A, Gerhard, Daniela S, Dancik, Vlado, Gill, Shubhroz, Hua, Bruce, Sharifnia, Tanaz, Viswanathan, Vasanthi, Zou, Yilong, Dela Cruz, Filemon, Kung, Andrew, Stockwell, Brent, Boehm, Jesse, Dempster, Josh, Manguso, Robert, Vazquez, Francisca, Cooper, Lee AD, Du, Yuhong, Ivanov, Andrey, Lonial, Sagar, Moreno, Carlos S, Niu, Qiankun, Owonikoko, Taofeek, Ramalingam, Suresh, Reyna, Matthew, Zhou, Wei, Grandori, Carla, Shmulevich, Ilya, Swisher, Elizabeth, Cai, Jitong, Chan, Issac S, Dunworth, Matthew, Ge, Yuchen, Georgess, Dan, Grasset, Eloïse M, Henriet, Elodie, Knútsdóttir, Hildur, Lerner, Michael G, Padmanaban, Veena, Perrone, Matthew C, Suhail, Yasir, Tsehay, Yohannes, Warrier, Manisha, Morrow, Quin, Nechiporuk, Tamilla, Long, Nicola, Saultz, Jennifer, Kaempf, Andy, Minnier, Jessica, Tognon, Cristina E, Kurtz, Stephen E, Agarwal, Anupriya, Brown, Jordana, Watanabe-Smith, Kevin, Vu, Tania Q, Jacob, Thomas, Yan, Yunqi, Robinson, Bridget, Lind, Evan F, Kosaka, Yoko, Demir, Emek, Estabrook, Joseph, Grzadkowski, Michael, Nikolova, Olga, Chen, Ken, Deneen, Ben, Liang, Han, Bassik, Michael C, Bhattacharya, Asmita, Brennan, Kevin, Curtis, Christina, Gevaert, Olivier, Ji, Hanlee P, Karlsson, Kasper AJ, Karagyozova, Kremena, Lo, Yuan-Hung, Liu, Katherine, Nakano, Michitaka, Sathe, Anuja, and Smith, Amber R

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Biotechnology, Genetics, Orphan Drug, Rare Diseases, 2.1 Biological and endogenous factors, Aetiology, Animals, Clinical Trials as Topic, Disease Models, Animal, Drug Delivery Systems, Genomics, Humans, Neoplasms, Tumor Escape, Tumor Microenvironment, Cancer Target Discovery and Development Network, Biological Sciences, Medical and Health Sciences, Developmental Biology, Biological sciences, Biomedical and clinical sciences
Abstract

The characterization of cancer genomes has provided insight into somatically altered genes across tumors, transformed our understanding of cancer biology, and enabled tailoring of therapeutic strategies. However, the function of most cancer alleles remains mysterious, and many cancer features transcend their genomes. Consequently, tumor genomic characterization does not influence therapy for most patients. Approaches to understand the function and circuitry of cancer genes provide complementary approaches to elucidate both oncogene and non-oncogene dependencies. Emerging work indicates that the diversity of therapeutic targets engendered by non-oncogene dependencies is much larger than the list of recurrently mutated genes. Here we describe a framework for this expanded list of cancer targets, providing novel opportunities for clinical translation.

Published
2021

4. NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia

Author

Scopim-Ribeiro, Renata, Machado-Neto, João Agostinho, Eide, Christopher A., Coelho-Silva, Juan Luiz, Fenerich, Bruna Alves, Fernandes, Jaqueline Cristina, Scheucher, Priscila Santos, Savage Stevens, Samantha L., de Melo Campos, Paula, Olalla Saad, Sara T., de Carvalho Palma, Leonardo, de Figueiredo-Pontes, Lorena Lobo, Simões, Belinda Pinto, Rego, Eduardo Magalhães, Tognon, Cristina E., Druker, Brian J., and Traina, Fabiola

Published
2021
Full Text
View/download PDF

5. Mapping the proteogenomic landscape enables prediction of drug response in acute myeloid leukemia

Author

Pino, James C., primary, Posso, Camilo, additional, Joshi, Sunil K., additional, Nestor, Michael, additional, Moon, Jamie, additional, Hansen, Joshua R., additional, Hutchinson-Bunch, Chelsea, additional, Gritsenko, Marina A., additional, Weitz, Karl K., additional, Watanabe-Smith, Kevin, additional, Long, Nicola, additional, McDermott, Jason E., additional, Druker, Brian J., additional, Liu, Tao, additional, Tyner, Jeffrey W., additional, Agarwal, Anupriya, additional, Traer, Elie, additional, Piehowski, Paul D., additional, Tognon, Cristina E., additional, Rodland, Karin D., additional, and Gosline, Sara J.C., additional

Published
2024
Full Text
View/download PDF

6. Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia

Author

White, Brian S., Khan, Suleiman A., Mason, Mike J., Ammad-ud-din, Muhammad, Potdar, Swapnil, Malani, Disha, Kuusanmäki, Heikki, Druker, Brian J., Heckman, Caroline, Kallioniemi, Olli, Kurtz, Stephen E., Porkka, Kimmo, Tognon, Cristina E., Tyner, Jeffrey W., Aittokallio, Tero, Wennerberg, Krister, and Guinney, Justin

Published
2021
Full Text
View/download PDF

12. Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoidderived hematologic malignancies

Author

Kurtz, Stephen E., Eide, Christopher A., Kaempf, Andy, Khanna, Vishesh, Savage, Samantha L., Rofelty, Angela, English, Isabel, Ho, Hibery, Pandya, Ravi, Bolosky, William J., Poon, Hoifung, Deininger, Michael W., Collins, Robert, Swords, Ronan T., Watts, Justin, Pollyea, Daniel A., Medeiros, Bruno C., Traer, Elie, Tognon, Cristina E., Mori, Motomi, Druker, Brian J., and Tyner, Jeffrey W.

Published
2017

14. Mass Spectrometry–Based Proteogenomics: New Therapeutic Opportunities for Precision Medicine.

Author

Joshi, Sunil K., Piehowski, Paul, Liu, Tao, Gosline, Sara J.C., McDermott, Jason E., Druker, Brian J., Traer, Elie, Tyner, Jeffrey W., Agarwal, Anupriya, Tognon, Cristina E., and Rodland, Karin D.

Subjects
TUMOR genetics, GENETIC mutation, INDIVIDUALIZED medicine, PROTEOMICS, MASS spectrometry, GENOMICS, GENOTYPES, SYMPTOMS, TUMORS, DRUG resistance in cancer cells, PHENOTYPES, CANCER patient medical care
Abstract

Proteogenomics refers to the integration of comprehensive genomic, transcriptomic, and proteomic measurements from the same samples with the goal of fully understanding the regulatory processes converting genotypes to phenotypes, often with an emphasis on gaining a deeper understanding of disease processes. Although specific genetic mutations have long been known to drive the development of multiple cancers, gene mutations alone do not always predict prognosis or response to targeted therapy. The benefit of proteogenomics research is that information obtained from proteins and their corresponding pathways provides insight into therapeutic targets that can complement genomic information by providing an additional dimension regarding the underlying mechanisms and pathophysiology of tumors. This review describes the novel insights into tumor biology and drug resistance derived from proteogenomic analysis while highlighting the clinical potential of proteogenomic observations and advances in technique and analysis tools. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Functional genomic landscape of acute myeloid leukaemia

Author

Tyner, Jeffrey W., Tognon, Cristina E., Bottomly, Daniel, Wilmot, Beth, Kurtz, Stephen E., Savage, Samantha L., Long, Nicola, Schultz, Anna Reister, Traer, Elie, Abel, Melissa, Agarwal, Anupriya, Blucher, Aurora, Borate, Uma, Bryant, Jade, Burke, Russell, Carlos, Amy, Carpenter, Richie, Carroll, Joseph, Chang, Bill H., Coblentz, Cody, d’Almeida, Amanda, Cook, Rachel, Danilov, Alexey, Dao, Kim-Hien T., Degnin, Michie, Devine, Deirdre, Dibb, James, Edwards, V, David K., Eide, Christopher A., English, Isabel, Glover, Jason, Henson, Rachel, Ho, Hibery, Jemal, Abdusebur, Johnson, Kara, Johnson, Ryan, Junio, Brian, Kaempf, Andy, Leonard, Jessica, Lin, Chenwei, Liu, Selina Qiuying, Lo, Pierrette, Loriaux, Marc M., Luty, Samuel, Macey, Tara, MacManiman, Jason, Martinez, Jacqueline, Mori, Motomi, Nelson, Dylan, Nichols, Ceilidh, Peters, Jill, Ramsdill, Justin, Rofelty, Angela, Schuff, Robert, Searles, Robert, Segerdell, Erik, Smith, Rebecca L., Spurgeon, Stephen E., Sweeney, Tyler, Thapa, Aashis, Visser, Corinne, Wagner, Jake, Watanabe-Smith, Kevin, Werth, Kristen, Wolf, Joelle, White, Libbey, Yates, Amy, Zhang, Haijiao, Cogle, Christopher R., Collins, Robert H., Connolly, Denise C., Deininger, Michael W., Drusbosky, Leylah, Hourigan, Christopher S., Jordan, Craig T., Kropf, Patricia, Lin, Tara L., Martinez, Micaela E., Medeiros, Bruno C., Pallapati, Rachel R., Pollyea, Daniel A., Swords, Ronan T., Watts, Justin M., Weir, Scott J., Wiest, David L., Winters, Ryan M., McWeeney, Shannon K., and Druker, Brian J.

Published
2018
Full Text
View/download PDF

18. Abstract 3172: Mapping the molecular landscape of acute myeloid leukemia enables prediction of drug response from proteogenomic data

Author

Pino, James C., primary, Posso, Camilo, additional, Joshi, Sunil K., additional, Nestor, Michael, additional, Moon, Jamie, additional, Hansen, Joshua R., additional, Gritsenko, Marina A., additional, Hutchinson-Bunch, Chelsea, additional, Weitz, Karl K., additional, Watanabe-Smith, Kevin, additional, McDermott, Jason E., additional, Druker, Brian J., additional, Liu, Tao, additional, Tyner, Jeffrey W., additional, Agarwal, Anupriya, additional, Traer, Elie, additional, Piehowski, Paul D., additional, Tognon, Cristina E., additional, Rodland, Karin D., additional, and Gosline, Sara J., additional

Published
2023
Full Text
View/download PDF

19. Supplementary Data from Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium

Author

Pikman, Yana, primary, Tasian, Sarah K., primary, Sulis, Maria Luisa, primary, Stevenson, Kristen, primary, Blonquist, Traci M., primary, Apsel Winger, Beth, primary, Cooper, Todd M., primary, Pauly, Melinda, primary, Maloney, Kelly W., primary, Burke, Michael J., primary, Brown, Patrick A., primary, Gossai, Nathan, primary, McNeer, Jennifer L., primary, Shukla, Neerav N., primary, Cole, Peter D., primary, Kahn, Justine M., primary, Chen, Jing, primary, Barth, Matthew J., primary, Magee, Jeffrey A., primary, Gennarini, Lisa, primary, Adhav, Asmani A., primary, Clinton, Catherine M., primary, Ocasio-Martinez, Nicole, primary, Gotti, Giacomo, primary, Li, Yuting, primary, Lin, Shan, primary, Imamovic, Alma, primary, Tognon, Cristina E., primary, Patel, Tasleema, primary, Faust, Haley L., primary, Contreras, Cristina F., primary, Cremer, Anjali, primary, Cortopassi, Wilian A., primary, Garrido Ruiz, Diego, primary, Jacobson, Matthew P., primary, Dharia, Neekesh V., primary, Su, Angela, primary, Robichaud, Amanda L., primary, Saur Conway, Amy, primary, Tarlock, Katherine, primary, Stieglitz, Elliot, primary, Place, Andrew E., primary, Puissant, Alexandre, primary, Hunger, Stephen P., primary, Kim, Annette S., primary, Lindeman, Neal I., primary, Gore, Lia, primary, Janeway, Katherine A., primary, Silverman, Lewis B., primary, Tyner, Jeffrey W., primary, Harris, Marian H., primary, Loh, Mignon L., primary, and Stegmaier, Kimberly, primary

Published
2023
Full Text
View/download PDF

20. Data from Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium

Author

Pikman, Yana, primary, Tasian, Sarah K., primary, Sulis, Maria Luisa, primary, Stevenson, Kristen, primary, Blonquist, Traci M., primary, Apsel Winger, Beth, primary, Cooper, Todd M., primary, Pauly, Melinda, primary, Maloney, Kelly W., primary, Burke, Michael J., primary, Brown, Patrick A., primary, Gossai, Nathan, primary, McNeer, Jennifer L., primary, Shukla, Neerav N., primary, Cole, Peter D., primary, Kahn, Justine M., primary, Chen, Jing, primary, Barth, Matthew J., primary, Magee, Jeffrey A., primary, Gennarini, Lisa, primary, Adhav, Asmani A., primary, Clinton, Catherine M., primary, Ocasio-Martinez, Nicole, primary, Gotti, Giacomo, primary, Li, Yuting, primary, Lin, Shan, primary, Imamovic, Alma, primary, Tognon, Cristina E., primary, Patel, Tasleema, primary, Faust, Haley L., primary, Contreras, Cristina F., primary, Cremer, Anjali, primary, Cortopassi, Wilian A., primary, Garrido Ruiz, Diego, primary, Jacobson, Matthew P., primary, Dharia, Neekesh V., primary, Su, Angela, primary, Robichaud, Amanda L., primary, Saur Conway, Amy, primary, Tarlock, Katherine, primary, Stieglitz, Elliot, primary, Place, Andrew E., primary, Puissant, Alexandre, primary, Hunger, Stephen P., primary, Kim, Annette S., primary, Lindeman, Neal I., primary, Gore, Lia, primary, Janeway, Katherine A., primary, Silverman, Lewis B., primary, Tyner, Jeffrey W., primary, Harris, Marian H., primary, Loh, Mignon L., primary, and Stegmaier, Kimberly, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Methods from The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells

Author

Nechiporuk, Tamilla, primary, Kurtz, Stephen E., primary, Nikolova, Olga, primary, Liu, Tingting, primary, Jones, Courtney L., primary, D'Alessandro, Angelo, primary, Culp-Hill, Rachel, primary, d'Almeida, Amanda, primary, Joshi, Sunil K., primary, Rosenberg, Mara, primary, Tognon, Cristina E., primary, Danilov, Alexey V., primary, Druker, Brian J., primary, Chang, Bill H., primary, McWeeney, Shannon K, primary, and Tyner, Jeffrey W., primary

Published
2023
Full Text
View/download PDF

22. Figure S5 from Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium

Author

Pikman, Yana, primary, Tasian, Sarah K., primary, Sulis, Maria Luisa, primary, Stevenson, Kristen, primary, Blonquist, Traci M., primary, Apsel Winger, Beth, primary, Cooper, Todd M., primary, Pauly, Melinda, primary, Maloney, Kelly W., primary, Burke, Michael J., primary, Brown, Patrick A., primary, Gossai, Nathan, primary, McNeer, Jennifer L., primary, Shukla, Neerav N., primary, Cole, Peter D., primary, Kahn, Justine M., primary, Chen, Jing, primary, Barth, Matthew J., primary, Magee, Jeffrey A., primary, Gennarini, Lisa, primary, Adhav, Asmani A., primary, Clinton, Catherine M., primary, Ocasio-Martinez, Nicole, primary, Gotti, Giacomo, primary, Li, Yuting, primary, Lin, Shan, primary, Imamovic, Alma, primary, Tognon, Cristina E., primary, Patel, Tasleema, primary, Faust, Haley L., primary, Contreras, Cristina F., primary, Cremer, Anjali, primary, Cortopassi, Wilian A., primary, Garrido Ruiz, Diego, primary, Jacobson, Matthew P., primary, Dharia, Neekesh V., primary, Su, Angela, primary, Robichaud, Amanda L., primary, Saur Conway, Amy, primary, Tarlock, Katherine, primary, Stieglitz, Elliot, primary, Place, Andrew E., primary, Puissant, Alexandre, primary, Hunger, Stephen P., primary, Kim, Annette S., primary, Lindeman, Neal I., primary, Gore, Lia, primary, Janeway, Katherine A., primary, Silverman, Lewis B., primary, Tyner, Jeffrey W., primary, Harris, Marian H., primary, Loh, Mignon L., primary, and Stegmaier, Kimberly, primary

Published
2023
Full Text
View/download PDF

23. Table S1 from Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium

Author

Pikman, Yana, primary, Tasian, Sarah K., primary, Sulis, Maria Luisa, primary, Stevenson, Kristen, primary, Blonquist, Traci M., primary, Apsel Winger, Beth, primary, Cooper, Todd M., primary, Pauly, Melinda, primary, Maloney, Kelly W., primary, Burke, Michael J., primary, Brown, Patrick A., primary, Gossai, Nathan, primary, McNeer, Jennifer L., primary, Shukla, Neerav N., primary, Cole, Peter D., primary, Kahn, Justine M., primary, Chen, Jing, primary, Barth, Matthew J., primary, Magee, Jeffrey A., primary, Gennarini, Lisa, primary, Adhav, Asmani A., primary, Clinton, Catherine M., primary, Ocasio-Martinez, Nicole, primary, Gotti, Giacomo, primary, Li, Yuting, primary, Lin, Shan, primary, Imamovic, Alma, primary, Tognon, Cristina E., primary, Patel, Tasleema, primary, Faust, Haley L., primary, Contreras, Cristina F., primary, Cremer, Anjali, primary, Cortopassi, Wilian A., primary, Garrido Ruiz, Diego, primary, Jacobson, Matthew P., primary, Dharia, Neekesh V., primary, Su, Angela, primary, Robichaud, Amanda L., primary, Saur Conway, Amy, primary, Tarlock, Katherine, primary, Stieglitz, Elliot, primary, Place, Andrew E., primary, Puissant, Alexandre, primary, Hunger, Stephen P., primary, Kim, Annette S., primary, Lindeman, Neal I., primary, Gore, Lia, primary, Janeway, Katherine A., primary, Silverman, Lewis B., primary, Tyner, Jeffrey W., primary, Harris, Marian H., primary, Loh, Mignon L., primary, and Stegmaier, Kimberly, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Table S1-S6 from The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells

Author

Nechiporuk, Tamilla, primary, Kurtz, Stephen E., primary, Nikolova, Olga, primary, Liu, Tingting, primary, Jones, Courtney L., primary, D'Alessandro, Angelo, primary, Culp-Hill, Rachel, primary, d'Almeida, Amanda, primary, Joshi, Sunil K., primary, Rosenberg, Mara, primary, Tognon, Cristina E., primary, Danilov, Alexey V., primary, Druker, Brian J., primary, Chang, Bill H., primary, McWeeney, Shannon K, primary, and Tyner, Jeffrey W., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Figure 6 from The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells

Author

Nechiporuk, Tamilla, primary, Kurtz, Stephen E., primary, Nikolova, Olga, primary, Liu, Tingting, primary, Jones, Courtney L., primary, D'Alessandro, Angelo, primary, Culp-Hill, Rachel, primary, d'Almeida, Amanda, primary, Joshi, Sunil K., primary, Rosenberg, Mara, primary, Tognon, Cristina E., primary, Danilov, Alexey V., primary, Druker, Brian J., primary, Chang, Bill H., primary, McWeeney, Shannon K, primary, and Tyner, Jeffrey W., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figure 1 from The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells

Author

Nechiporuk, Tamilla, primary, Kurtz, Stephen E., primary, Nikolova, Olga, primary, Liu, Tingting, primary, Jones, Courtney L., primary, D'Alessandro, Angelo, primary, Culp-Hill, Rachel, primary, d'Almeida, Amanda, primary, Joshi, Sunil K., primary, Rosenberg, Mara, primary, Tognon, Cristina E., primary, Danilov, Alexey V., primary, Druker, Brian J., primary, Chang, Bill H., primary, McWeeney, Shannon K, primary, and Tyner, Jeffrey W., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figure 5 from The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells

Author

Nechiporuk, Tamilla, primary, Kurtz, Stephen E., primary, Nikolova, Olga, primary, Liu, Tingting, primary, Jones, Courtney L., primary, D'Alessandro, Angelo, primary, Culp-Hill, Rachel, primary, d'Almeida, Amanda, primary, Joshi, Sunil K., primary, Rosenberg, Mara, primary, Tognon, Cristina E., primary, Danilov, Alexey V., primary, Druker, Brian J., primary, Chang, Bill H., primary, McWeeney, Shannon K, primary, and Tyner, Jeffrey W., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Methods from Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium

Author

Pikman, Yana, primary, Tasian, Sarah K., primary, Sulis, Maria Luisa, primary, Stevenson, Kristen, primary, Blonquist, Traci M., primary, Apsel Winger, Beth, primary, Cooper, Todd M., primary, Pauly, Melinda, primary, Maloney, Kelly W., primary, Burke, Michael J., primary, Brown, Patrick A., primary, Gossai, Nathan, primary, McNeer, Jennifer L., primary, Shukla, Neerav N., primary, Cole, Peter D., primary, Kahn, Justine M., primary, Chen, Jing, primary, Barth, Matthew J., primary, Magee, Jeffrey A., primary, Gennarini, Lisa, primary, Adhav, Asmani A., primary, Clinton, Catherine M., primary, Ocasio-Martinez, Nicole, primary, Gotti, Giacomo, primary, Li, Yuting, primary, Lin, Shan, primary, Imamovic, Alma, primary, Tognon, Cristina E., primary, Patel, Tasleema, primary, Faust, Haley L., primary, Contreras, Cristina F., primary, Cremer, Anjali, primary, Cortopassi, Wilian A., primary, Garrido Ruiz, Diego, primary, Jacobson, Matthew P., primary, Dharia, Neekesh V., primary, Su, Angela, primary, Robichaud, Amanda L., primary, Saur Conway, Amy, primary, Tarlock, Katherine, primary, Stieglitz, Elliot, primary, Place, Andrew E., primary, Puissant, Alexandre, primary, Hunger, Stephen P., primary, Kim, Annette S., primary, Lindeman, Neal I., primary, Gore, Lia, primary, Janeway, Katherine A., primary, Silverman, Lewis B., primary, Tyner, Jeffrey W., primary, Harris, Marian H., primary, Loh, Mignon L., primary, and Stegmaier, Kimberly, primary

Published
2023
Full Text
View/download PDF

29. Data from The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells

Author

Nechiporuk, Tamilla, primary, Kurtz, Stephen E., primary, Nikolova, Olga, primary, Liu, Tingting, primary, Jones, Courtney L., primary, D'Alessandro, Angelo, primary, Culp-Hill, Rachel, primary, d'Almeida, Amanda, primary, Joshi, Sunil K., primary, Rosenberg, Mara, primary, Tognon, Cristina E., primary, Danilov, Alexey V., primary, Druker, Brian J., primary, Chang, Bill H., primary, McWeeney, Shannon K, primary, and Tyner, Jeffrey W., primary

Published
2023
Full Text
View/download PDF

30. Supplementary Figure 2 from The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells

Author

Nechiporuk, Tamilla, primary, Kurtz, Stephen E., primary, Nikolova, Olga, primary, Liu, Tingting, primary, Jones, Courtney L., primary, D'Alessandro, Angelo, primary, Culp-Hill, Rachel, primary, d'Almeida, Amanda, primary, Joshi, Sunil K., primary, Rosenberg, Mara, primary, Tognon, Cristina E., primary, Danilov, Alexey V., primary, Druker, Brian J., primary, Chang, Bill H., primary, McWeeney, Shannon K, primary, and Tyner, Jeffrey W., primary

Published
2023
Full Text
View/download PDF

31. Supplementary Figure 4 from The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells

Author

Nechiporuk, Tamilla, primary, Kurtz, Stephen E., primary, Nikolova, Olga, primary, Liu, Tingting, primary, Jones, Courtney L., primary, D'Alessandro, Angelo, primary, Culp-Hill, Rachel, primary, d'Almeida, Amanda, primary, Joshi, Sunil K., primary, Rosenberg, Mara, primary, Tognon, Cristina E., primary, Danilov, Alexey V., primary, Druker, Brian J., primary, Chang, Bill H., primary, McWeeney, Shannon K, primary, and Tyner, Jeffrey W., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure 3 from The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells

Author

Nechiporuk, Tamilla, primary, Kurtz, Stephen E., primary, Nikolova, Olga, primary, Liu, Tingting, primary, Jones, Courtney L., primary, D'Alessandro, Angelo, primary, Culp-Hill, Rachel, primary, d'Almeida, Amanda, primary, Joshi, Sunil K., primary, Rosenberg, Mara, primary, Tognon, Cristina E., primary, Danilov, Alexey V., primary, Druker, Brian J., primary, Chang, Bill H., primary, McWeeney, Shannon K, primary, and Tyner, Jeffrey W., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Figure and Table Legends from ETV6-NTRK3–Mediated Breast Epithelial Cell Transformation Is Blocked by Targeting the IGF1R Signaling Pathway

Author

Tognon, Cristina E., primary, Somasiri, Aruna M., primary, Evdokimova, Valentina E., primary, Trigo, Genny, primary, Uy, Evett E., primary, Melnyk, Nataliya, primary, Carboni, Joan M., primary, Gottardis, Marco M., primary, Roskelley, Calvin D., primary, Pollak, Michael, primary, and Sorensen, Poul H.B., primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figures 1-6, Table 1 from ETV6-NTRK3–Mediated Breast Epithelial Cell Transformation Is Blocked by Targeting the IGF1R Signaling Pathway

Author

Tognon, Cristina E., primary, Somasiri, Aruna M., primary, Evdokimova, Valentina E., primary, Trigo, Genny, primary, Uy, Evett E., primary, Melnyk, Nataliya, primary, Carboni, Joan M., primary, Gottardis, Marco M., primary, Roskelley, Calvin D., primary, Pollak, Michael, primary, and Sorensen, Poul H.B., primary

Published
2023
Full Text
View/download PDF

37. Data from Therapeutically Targetable ALK Mutations in Leukemia

Author

Maxson, Julia E., primary, Davare, Monika A., primary, Luty, Samuel B., primary, Eide, Christopher A., primary, Chang, Bill H., primary, Loriaux, Marc M., primary, Tognon, Cristina E., primary, Bottomly, Daniel, primary, Wilmot, Beth, primary, McWeeney, Shannon K., primary, Druker, Brian J., primary, and Tyner, Jeffrey W., primary

Published
2023
Full Text
View/download PDF

40. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia

Author

Bottomly, Daniel, primary, Long, Nicola, additional, Schultz, Anna Reister, additional, Kurtz, Stephen E., additional, Tognon, Cristina E., additional, Johnson, Kara, additional, Abel, Melissa, additional, Agarwal, Anupriya, additional, Avaylon, Sammantha, additional, Benton, Erik, additional, Blucher, Aurora, additional, Borate, Uma, additional, Braun, Theodore P., additional, Brown, Jordana, additional, Bryant, Jade, additional, Burke, Russell, additional, Carlos, Amy, additional, Chang, Bill H., additional, Cho, Hyun Jun, additional, Christy, Stephen, additional, Coblentz, Cody, additional, Cohen, Aaron M., additional, d’Almeida, Amanda, additional, Cook, Rachel, additional, Danilov, Alexey, additional, Dao, Kim-Hien T., additional, Degnin, Michie, additional, Dibb, James, additional, Eide, Christopher A., additional, English, Isabel, additional, Hagler, Stuart, additional, Harrelson, Heath, additional, Henson, Rachel, additional, Ho, Hibery, additional, Joshi, Sunil K., additional, Junio, Brian, additional, Kaempf, Andy, additional, Kosaka, Yoko, additional, Laderas, Ted, additional, Lawhead, Matt, additional, Lee, Hyunjung, additional, Leonard, Jessica T., additional, Lin, Chenwei, additional, Lind, Evan F., additional, Liu, Selina Qiuying, additional, Lo, Pierrette, additional, Loriaux, Marc M., additional, Luty, Samuel, additional, Maxson, Julia E., additional, Macey, Tara, additional, Martinez, Jacqueline, additional, Minnier, Jessica, additional, Monteblanco, Andrea, additional, Mori, Motomi, additional, Morrow, Quinlan, additional, Nelson, Dylan, additional, Ramsdill, Justin, additional, Rofelty, Angela, additional, Rogers, Alexandra, additional, Romine, Kyle A., additional, Ryabinin, Peter, additional, Saultz, Jennifer N., additional, Sampson, David A., additional, Savage, Samantha L., additional, Schuff, Robert, additional, Searles, Robert, additional, Smith, Rebecca L., additional, Spurgeon, Stephen E., additional, Sweeney, Tyler, additional, Swords, Ronan T., additional, Thapa, Aashis, additional, Thiel-Klare, Karina, additional, Traer, Elie, additional, Wagner, Jake, additional, Wilmot, Beth, additional, Wolf, Joelle, additional, Wu, Guanming, additional, Yates, Amy, additional, Zhang, Haijiao, additional, Cogle, Christopher R., additional, Collins, Robert H., additional, Deininger, Michael W., additional, Hourigan, Christopher S., additional, Jordan, Craig T., additional, Lin, Tara L., additional, Martinez, Micaela E., additional, Pallapati, Rachel R., additional, Pollyea, Daniel A., additional, Pomicter, Anthony D., additional, Watts, Justin M., additional, Weir, Scott J., additional, Druker, Brian J., additional, McWeeney, Shannon K., additional, and Tyner, Jeffrey W., additional

Published
2022
Full Text
View/download PDF

41. Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms

Author

Machado-Neto, João Agostinho, Fenerich, Bruna Alves, Scopim-Ribeiro, Renata, Eide, Christopher A., Coelho-Silva, Juan Luiz, Dechandt, Carlos Roberto Porto, Fernandes, Jaqueline Cristina, Rodrigues Alves, Ana Paula Nunes, Scheucher, Priscila Santos, Simões, Belinda Pinto, Alberici, Luciane Carla, de Figueiredo Pontes, Lorena Lôbo, Tognon, Cristina E., Druker, Brian J., Rego, Eduardo Magalhães, and Traina, Fabiola

Published
2018
Full Text
View/download PDF

43. Secondary fusion proteins as a mechanism of BCR::ABL1 kinase‐independent resistance in chronic myeloid leukaemia.

Author

Barnes, Evan J., Eide, Christopher A., Kaempf, Andy, Bottomly, Daniel, Romine, Kyle A., Wilmot, Beth, Saunders, Dominick, McWeeney, Shannon K., Tognon, Cristina E., and Druker, Brian J.

Subjects
CHRONIC myeloid leukemia, CHIMERIC proteins, GENE expression, PROTEIN-tyrosine kinase inhibitors, DRUG resistance
Abstract

Summary: Drug resistance in chronic myeloid leukaemia (CML) may occur via mutations in the causative BCR::ABL1 fusion or BCR::ABL1‐independent mechanisms. We analysed 48 patients with BCR::ABL1‐independent resistance for the presence of secondary fusion genes by RNA sequencing. We identified 10 of the most frequently detected secondary fusions in 21 patients. Validation studies, cell line models, gene expression analysis and drug screening revealed differences with respect to proliferation rate, differentiation and drug sensitivity. Notably, expression of RUNX1::MECOM led to resistance to ABL1 tyrosine kinase inhibitors in vitro. These results suggest secondary fusions contribute to BCR::ABL1‐independent resistance and may be amenable to combined therapies. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

44. Evaluation of Differential Peptide Loading on Tandem Mass Tag-Based Proteomic and Phosphoproteomic Data Quality

Author

Sanford, James A., primary, Wang, Yang, additional, Hansen, Joshua R., additional, Gritsenko, Marina A., additional, Weitz, Karl K., additional, Sagendorf, Tyler J., additional, Tognon, Cristina E., additional, Petyuk, Vladislav A., additional, Qian, Wei-Jun, additional, Liu, Tao, additional, Druker, Brian J., additional, Rodland, Karin D., additional, and Piehowski, Paul D., additional

Published
2021
Full Text
View/download PDF

45. Novel Combination Therapy of Venetoclax and Ruxolitinib in the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia

Author

Borate, Uma, primary, Saultz, Jennifer N., additional, Kaempf, Andy, additional, Minnier, Jessica, additional, Tognon, Cristina E., additional, Kurtz, Stephen E., additional, Eide, Christopher A., additional, Patel, Prapti A., additional, Madanat, Yazan F., additional, Clement, Peter, additional, Avaylon, Sammantha, additional, Misra, Shikha, additional, Druker, Brian J., additional, and Tyner, Jeffrey W., additional

Published
2021
Full Text
View/download PDF

46. Comprehensive molecular characterization of a rare case of Philadelphia chromosome--positive acute myeloid leukemia.

Author

Rosenberg, Mara W., Savage, Samantha L., Eide, Christopher A., Schultz, Anna Reister, Cook, Rachel J., Press, Richard D., Rempfer, Carole, Eickelberg, Garrett, Wilmot, Beth, McWeeney, Shannon K., Tyner, Jeffrey W., Druker, Brian J., and Tognon, Cristina E.

Subjects
PHILADELPHIA chromosome, LYMPHOBLASTIC leukemia, LEUKEMIA, STEM cell transplantation, MYELODYSPLASTIC syndromes, PATIENTS
Abstract

The Philadelphia chromosome (Ph) resulting from the t(9;22) translocation generates the oncogenic BCR::ABL1 fusion protein that is most commonly associated with chronic myeloid leukemia (CML) and Ph-positive (Ph+) acute lymphoblastic leukemia (ALL). There are also rare instances of patients (≤1%) with newly diagnosed acute myeloid leukemia (AML) that harbor this translocation (Paietta et al., Leukemia 12: 1881 [1998]; Keung et al., Leuk Res 28: 579 [2004]; Soupir et al., Am J Clin Pathol 127: 642 [2007]). AML with BCR::ABL has only recently been provisionally classified by the World Health Organization as a diagnostically distinct subtype of AML. Discernment from the extremely close differential diagnosis of myeloid blast crisis CML is challenging, largely relying on medical history rather than clinical characteristics (Arber et al., Blood 127: 2391 [2016]). To gain insight into the genomic features underlying the evolution of AML with BCR:: ABL, we identified a patient presenting with a high-risk myelodysplastic syndrome that acquired a BCR::ABL alteration after a peripheral blood stem cell transplant. Serial samples were collected and analyzed using whole-exome sequencing, RNA-seq, and ex vivo functional drug screens. Persistent subclones were identified, both at diagnosis and at relapse, including an SF3B1p.Lys700Glu mutation that later cooccurred with an NRASp.Gly12Cys mutation. Functional ex vivo drug screening performed on primary patient cells suggested that combination therapies of ABL1 with RAS or PI3K pathway inhibitors could have augmented the patient's response throughout the course of disease. Together, our findings argue for the importance of genomic profiling and the potential value of ABL1 inhibitor--inclusive combination treatment strategies in patients with this rare disease. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

48. The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance

Author

Joshi, Sunil K., primary, Nechiporuk, Tamilla, additional, Bottomly, Daniel, additional, Piehowski, Paul D., additional, Reisz, Julie A., additional, Pittsenbarger, Janét, additional, Kaempf, Andy, additional, Gosline, Sara J.C., additional, Wang, Yi-Ting, additional, Hansen, Joshua R., additional, Gritsenko, Marina A., additional, Hutchinson, Chelsea, additional, Weitz, Karl K., additional, Moon, Jamie, additional, Cendali, Francesca, additional, Fillmore, Thomas L., additional, Tsai, Chia-Feng, additional, Schepmoes, Athena A., additional, Shi, Tujin, additional, Arshad, Osama A., additional, McDermott, Jason E., additional, Babur, Ozgun, additional, Watanabe-Smith, Kevin, additional, Demir, Emek, additional, D'Alessandro, Angelo, additional, Liu, Tao, additional, Tognon, Cristina E., additional, Tyner, Jeffrey W., additional, McWeeney, Shannon K., additional, Rodland, Karin D., additional, Druker, Brian J., additional, and Traer, Elie, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results